Massachusetts General Hospital
Boston, Massachusetts, 02140, United States
NCT Number: NCT03873610
This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. Both programs are 8 week group programs.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02140, United States
Neurofibromatosis (NFs) are rare genetic conditions with cure. Adolescents with NF experience more symptoms of depression and anxiety, higher levels of stress associated with coping with NF symptoms, lower levels of self esteem, difficulties with social skills and social support, high rates of learning disabilities, and more pain as compared with the general population norms.
The aims of this study are to compare the effect of two stress and symptom management programs tailored for adolescents with neurofibromatosis on quality of life and psychosocial functioning. We will also examine the degree to which treatment-dependent improvements in quality of life are mediated by improvements in depression, pain intensity and pain interference.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
Time frame: 0 weeks, 8 weeks, 6 months,12 months
World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Time frame: 0 weeks, 8 weeks, 6 months,12 months
World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Time frame: 0 weeks, 8 weeks, 6 months,12 months
World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Time frame: 0 weeks, 8 weeks, 6 months, 12 months
World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Time frame: 0 weeks, 8 weeks, 6 months, 12 months
Patient Health Questionnaire (PHQ-9) Adolescent Version; 0-27; Higher score indicates more symptoms of depression
Time frame: 0 weeks, 8 weeks, 6 months, 12 months
Generalized Anxiety Disorder (GAD-7) Questionnaire; 0-21; Higher score indicates more symptoms of anxiety
Time frame: 0 weeks, 8 weeks, 6 months, 12 months
Numerical Rating Scale; 0-10; Higher score indicates more intense pain.
Time frame: 0 weeks, 8 weeks, 6 months, 12 months
Pain Interference Index (PII); 0-36; Higher score indicates more pain interference
Massachusetts General Hospital
Other
Resiliency Training in Adolescents With NF1 and NF2; A Randomized Controlled Trial Via Secure Live Video Conferencing to Improve Emotional, Social and Physical Function
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03406208
Behavior, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Boston, Massachusetts, United States
View Trial DetailsNCT04474678
Brain Diseases, Brain Neoplasms
Sankt Veit im Pongau, State of Salzburg, Austria
View Trial DetailsNCT01682811
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Milwaukee, Wisconsin, United States
View Trial DetailsNCT03513757
Abdominal Neoplasm, Abdominal Neoplasms
Milwaukee, Wisconsin, United States
View Trial Details